Latest Adalimumab Stories
ABBOTT PARK, Ill., April 20, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2011. Diluted earnings per share, excluding specified items, were $0.91, reflecting 12.3 percent growth.
SILVER SPRING, Md., April 15, 2011 /PRNewswire-USNewswire/ --The U.S.
The American College of Rheumatology has developed new guidelines for starting and monitoring treatments for children with juvenile idiopathic arthritis.
A recent trial of rituximab in combination with a tumor necrosis factor (TNF) inhibitor and methotrexate (MTX) in patients with active rheumatoid arthritis (RA) found the safety profile to be consistent with other RA trials with TNF inhibitors.
Pfizer said on Friday that its rheumatoid arthritis drug met the main goals of a late-stage clinical trial.
SAN DIEGO, March 1, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today highlighted its financial results and product development progress for the year ended December 31, 2010. "Prometheus had another record year in 2010, our 14th consecutive year of sales growth," said Joseph M.
Some biologic drugs may be safer than others according to a new systematic review by Cochrane researchers.
ABBOTT PARK, Ill., Jan. 26, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2010. Diluted earnings per share, excluding specified items, were $1.30, reflecting 10.2 percent growth.
EXTON, Pa., Dec. 20, 2010 /PRNewswire/ -- In its recently released annual 2010 update, ChartTrendsÂ®: Biologics in Rheumatoid Arthritis, BioTrends Research Group, Inc.
BURLINGTON, Mass., Dec.
- One of the side scenes of the stage in a theater, or the space included between the side scenes.
- The outside stock exchange, or “curb market,” of Paris.
- A flute or groove on the blade of a sword.
- A section of stage scenery placed in a wing of a theatre.